Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Other Accumulated Expenses (2022 - 2025)

Historic Other Accumulated Expenses for Capricor Therapeutics (CAPR) over the last 4 years, with Q3 2025 value amounting to $2.6 million.

  • Capricor Therapeutics' Other Accumulated Expenses rose 2612155.0% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 2612155.0%. This contributed to the annual value of $435712.0 for FY2024, which is 425712.0% up from last year.
  • Per Capricor Therapeutics' latest filing, its Other Accumulated Expenses stood at $2.6 million for Q3 2025, which was up 2612155.0% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Capricor Therapeutics' Other Accumulated Expenses registered a high of $2.6 million during Q3 2025, and its lowest value of $10000.0 during Q4 2023.
  • Over the past 4 years, Capricor Therapeutics' median Other Accumulated Expenses value was $54706.0 (recorded in 2022), while the average stood at $485865.9.
  • As far as peak fluctuations go, Capricor Therapeutics' Other Accumulated Expenses plummeted by 8879.35% in 2023, and later soared by 2612155.0% in 2025.
  • Capricor Therapeutics' Other Accumulated Expenses (Quarter) stood at $89234.0 in 2022, then crashed by 88.79% to $10000.0 in 2023, then surged by 4257.12% to $435712.0 in 2024, then surged by 501.81% to $2.6 million in 2025.
  • Its Other Accumulated Expenses was $2.6 million in Q3 2025, compared to $1.4 million in Q2 2025 and $201681.0 in Q1 2025.